Latest Conference Articles

December 6th 2015, 2:01pm

ASH Annual Meeting and Exposition

The addition of idelalisib to bendamustine and rituximab (BR) reduced the risk of progression or death by 67% compared with BR alone for patients with relapsed/refractory chronic lymphocytic leukemia.

December 6th 2015, 12:05pm

ASH Annual Meeting and Exposition

An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

December 6th 2015, 9:00am

ASH Annual Meeting and Exposition

David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.

December 5th 2015, 4:13pm

ASH Annual Meeting and Exposition

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

December 5th 2015, 4:00pm

ASH Annual Meeting and Exposition

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.

December 5th 2015, 3:32pm

ASH Annual Meeting and Exposition

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

December 5th 2015, 2:25pm

ASH Annual Meeting and Exposition

An all-oral triplet therapy of ixazomib, cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma.

December 5th 2015, 1:49pm

ASH Annual Meeting and Exposition

Treatment with the CD38 monoclonal antibody daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

December 5th 2015, 12:29pm

ASH Annual Meeting and Exposition

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

December 5th 2015, 11:46am

ASH Annual Meeting and Exposition

The combination of elotuzumab, lenalidomide, and dexamethasone showed sustained improvements in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma.

December 5th 2015, 10:15am

ASH Annual Meeting and Exposition

Induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and overall survival compared with lenalidomide and dexamethasone alone for patients with untreated multiple myeloma.

December 5th 2015, 9:14am

ASH Annual Meeting and Exposition

Treatment with carfilzomib reduced the risk of progression or death by 47% compared with bortezomib for patients with relapsed multiple myeloma.

December 4th 2015, 2:45pm

ASH Annual Meeting and Exposition

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

December 4th 2015, 11:21am

ASH Annual Meeting and Exposition

Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

December 3rd 2015, 12:32pm

ASH Annual Meeting and Exposition

Marcel R.M. van den Brink, MD, PhD, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

December 3rd 2015, 11:15am

ASH Annual Meeting and Exposition

In less than 5 years, the treatment landscape for patients with hematologic malignancies has undergone a dramatic transformation, with continued advancements and pivotal data being presented at the 2015 ASH Annual Meeting.

November 27th 2015, 12:01pm

SMR Congress

Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.

November 23rd 2015, 1:13pm

Society for Neuro-Oncology Annual Meeting

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

November 23rd 2015, 11:11am

Society for Neuro-Oncology Annual Meeting

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

November 22nd 2015, 5:48pm

SMR Congress

Treatment with the combination of vemurafenib and cobimetinib improved overall survival by 4.9 months compared with vemurafenib alone for patients with BRAF mutation-positive advanced melanoma.